Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology

Written By Yiran Gan

2019.12.17

Lih-Fen Lue . Yu-Min Kuo . Marwan Sabbagh

Neurol Ther (2019) 8 (Suppl 2):S95–S111

Yiran Gan
Previous

Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease
Next

Combined Assessment of Serum Alpha-Synuclein and Rab35 is a Better Biomarker for Parkinson's Disease